(11) 98705-3426
TrademarkIQ iconTrademarkIQ
Back to search
Official data from INPI

INIBIDORES DE ECTONUCLEOTIDASE E MÉTODOS DE USO DOS MESMOS

ConcedidaInvention PatentPCT · US2019038245

Application data

Number

112020025132

Type

Invention Patent

Filing

06/20/2019

Publication

03/23/2021

PCT

US2019038245

Progress at the INPI

  1. Filing06/20/19
  2. Publication03/23/21
  3. Examination
  4. Allowance08/22/23
  5. Grant10/10/23
  6. In force06/20/39

The patent was granted on 10/10/2023 and is in force until 06/20/2039. Until then, no one may make, use or sell the invention in Brazil without the owner's authorisation.

Protection valid until:06/20/2039

Leave your contact and we will alert you

We track INPI publications and let you know as soon as this case moves.

We use your details only for this alert.

Latest action published by the INPI: 10/10/2023. We update with every new RPI gazette, published weekly.

Applicants and inventors

Applicants

ANTENGENE THERAPEUTICS LIMITED

HK

CALITHERA BIOSCIENCES INC.

US

Inventors

J. L. (pessoa física)

US

L. C. (pessoa física)

US

R. B. (pessoa física)

US

Technical data

Priority claims

US

62/688,225 · 06/21/2018

US

62/827,505 · 04/01/2019

Abstract

A presente invenção refere-se a compostos heterocíclicos e preparações farmacêuticas dos mesmos. A invenção ainda se refere aos métodos de tratamento ou prevenção do câncer usando os compostos heterocíclicos da invenção.

Prosecution history

Publications in the Brazilian Industrial Property Gazette (RPI).

Concessão da patente

#16.1

Prazo de Validade: 20 (vinte) anos contados a partir de 20/06/2019, observadas as condições legais

10/10/2023

RPI 2753

Transferência deferida

#25.1

09/05/2023

RPI 2748

Deferimento

#9.1

08/22/2023

RPI 2746

Parecer de pré-exame

#6.23

04/11/2023

RPI 2727

Notificação de entrada na fase nacional - PCT

#1.3

03/23/2021

RPI 2620

Alteração de dados cadastrais

#1.1

12/22/2020

RPI 2607

Patent monitoring

Track this patent in real time.

Receive alerts on INPI events, decisions, and expiry dates for your portfolio.